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Background: This study assessed the immunogenicity of pegvaliase (recombinant Anabaena variabilis phenylala-
nine [Phe] ammonia lyase [PAL] conjugated with polyethylene glycol [PEG]) treatment in adults with phenylke-
tonuria (PKU) and its impact on safety and efﬁcacy.
Methods: Immunogenicitywas assessed during induction, upward titration, andmaintenance dosing regimens in
adultswith PKU (n=261). Total antidrug antibodies (ADA), neutralizing antibodies, immunoglobulin (Ig)Mand
IgG antibodies against PAL and PEG, IgG and IgM circulating immune complex (CIC) levels, complement compo-
nents 3 and 4 (C3/C4), plasma Phe, and safety were assessed at baseline and throughout the study. Pegvaliase-
speciﬁc IgE levels were measured in patients after hypersensitivity adverse events (HAE).
Findings:All patients developedADAagainst PAL, peakingby6months and then stabilizing.Most developed tran-
sient antibody responses against PEG, peaking by 3 months, then returning to baseline by 9 months. Binding of
ADA to pegvaliase led to CIC formation and complement activation, which were highest during early treatment.
Blood Phe decreased over time as CIC levels and complement activation declined and pegvaliase dosage in-
creased. HAEsweremost frequent during early treatment and declined over time. Nopatientwith acute systemic
hypersensitivity events tested positive for pegvaliase-speciﬁc IgE near the time of the event. Laboratory evidence
was consistent with immune complex-mediated type III hypersensitivity. No evidence of pegvaliase-associated
IC-mediated end organ damage was noted.
Interpretation: Despite a universal ADA response post-pegvaliase administration, adult patients with PKU
achieved substantial and sustained blood Phe reductions with a manageable safety proﬁle.
Fund: BioMarin Pharmaceutical Inc.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
Phenylketonuria (PKU; OMIM 261600), also known as phenylala-
nine hydroxylase (PAH) deﬁciency, is a rare, autosomal recessive dis-
ease resulting in high concentrations of blood phenylalanine (Phe).
Elevated blood Phe in adults is associated with executive dysfunction
and signiﬁcant behavioral and psychiatric problems, which lead to a
negative impact on patient quality of life [1–4]. A recent survey of
patients with PKU reported that only 23% of adult patients [5] were
able to maintain blood Phe within the therapeutic range of 120 to
360 μmol/L [6].
Treatment for PKU includes severe restriction of dietary Phe, supple-
mented with Phe-free or low-Phe amino acid-modiﬁed medical foods,
alone or in combination with sapropterin dihydrochloride (KUVAN®,
BioMarin Pharmaceutical Inc., Novato, CA). However, for most adults
with PKU, these treatments are insufﬁcient tomanage their chronic dis-
ease due to long-term adherence issues or inadequate Phe-lowering ef-
fects [1,5,7–9].
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Pegvaliase (Palynziq™, BioMarin Pharmaceutical Inc., Novato, CA) is
a bacterially derived (recombinant Anabaena variabilis [rAv]) phenylal-
anine ammonia lyase (PAL) conjugated with polyethylene glycol (PEG)
and produced in Escherichia coli. PEGylation of the PAL enzyme reduces
immune recognition and improves pharmacodynamic stability.
Pegvaliase, an enzyme substitution therapy, metabolizes Phe to trans-
cinnamic acid and ammonia. Based on results from phase 3 studies
showing substantial and sustained reductions in mean blood Phe and
long-term improvements in symptoms of inattention and mood,
pegvaliase is approved in the United States to treat adult patients with
PKU and is the ﬁrst bacterially derived therapeutic protein approved
for the treatment of a chronic disease [4,7,10].
Biologics, including enzyme replacement therapies (ERTs), are used
for a range of disease treatments. Many ERTs induce antidrug antibodies
(ADAs) that result in adverse events (AEs) and reduced efﬁcacy, and/or
impact pharmacokinetics [11,12]. AEs may be due to the formation of
drug/ADA circulating immune complex (CIC) intermediateswith down-
stream effects [13]. Neutralizing antibody (NAb) formation can inhibit
enzymatic activity and efﬁcacy [14,15]. Given that pegvaliase contains
bacterially derived PAL, development of ADAs after treatment with
pegvaliase is expected. Further, an increasing number of reports docu-
ment development of anti-PEG antibodies following treatment with
PEGylated therapeutics [16–18]. Anti-PEG antibodies have been associ-
atedwith reduced efﬁcacy and hypersensitivitywith some therapeutics,
but it is unclear why only some PEGylated therapeutics induce a clini-
cally relevant anti-PEG antibody response [16,18]. Therefore, the objec-
tive of this study was to comprehensively characterize the
immunogenicity proﬁle after pegvaliase treatment, including anti-PEG
and anti-PAL antibody responses and CIC and complement levels, and
assess the impact of that response on safety and efﬁcacy.
2. Materials and methods
The methodology has been previously described for the phase 3
PRISM-1 and PRISM-2 studies (ClinicalTrials.gov Identiﬁers:
NCT01819727, NCT01889862) [4]. Patients in the phase 3 trials self-
administered subcutaneous pegvaliase using an induction, titration,
and maintenance dosing schedule. Patients were randomized in
PRISM-1 to titrate to a maintenance dose of 20 mg/day or 40 mg/day
of pegvaliase. In PRISM-2, dosing of 5 to 60 mg/day of pegvaliase was
allowed [4]. Details on the structural and biochemical characteristics
of rAvPAL (accession number: 3CZO) have previously been reported
[19]. Baseline blood Phe and immunogenicity data are provided
(Supplemental Table 1). Informed consent was obtained from each par-
ticipant and the PRISM studies were conducted in accordance with the
Declaration of Helsinki. Prior to initiating the study, the investigator at
each study site obtained written conﬁrmation that the institutional re-
view board (IRB)was properly constituted and compliant with Interna-
tional Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use and Good Clinical Prac-
tice requirements and applicable laws and local regulations. A complete
list of the IRBs is provided in the Supplemental Text. An independent
data monitoring committee governed the conduct of the phase 3 trials.
2.1. Assessments
Blood Phe (measured in plasma), immunogenicity (measured in
serum), and safety assessments were conducted at baseline and at
least monthly during the induction, titration, and maintenance periods
until 1 year on treatment, at which point assessments were conducted
bimonthly. Established CLIA/CAP methods were used to measure Phe,
and ADA assays were validated to assess serum positivity and titers
for anti-pegvaliase total antibodies (TAb), PAL immunoglobulin (Ig)
M, PAL IgG, PEG IgM, PEG IgG, and antibodies that inhibit pegvaliase en-
zyme activity (NAb). IgG and IgMCICsweremeasured at baseline and at
approximately 12, 36, 60, 84, and 108 weeks after ﬁrst dose. For acute
systemic hypersensitivity events (see “Safety measurements”), a clinic
visit was required for measurement of anti-pegvaliase IgE and other
clinical laboratory parameters (high-sensitivity C-reactive protein, com-
plement components 3 and 4 [C3/C4] antigens, and tryptase).
2.2. Safety measurements
Safety was monitored using clinical laboratory tests (chemistry, he-
matology, and urinalysis), vital signs, physical examinations, electrocar-
diograms, and AEs (coded by MedDRA preferred terms [20]). AEs
suggestive of immune complex (IC) formation were assessed; these in-
cluded arthralgia/arthritis, generalized skin reaction lasting ≥14 days,
urticaria lasting ≥14 days, lymphadenopathy lasting ≥14 days, serum
sickness-like reaction, serious infections, and ischemic heart disease.
Search strategies for laboratory data identiﬁed abnormalities that
could be reﬂective of IC disease. Hypersensitivity adverse events
(HAEs) were identiﬁed using broad modiﬁed hypersensitivity Stan-
dardized MedDRA Queries (SMQ), which included additional preferred
Research in context
Evidence before this study
Phenylketonuria (PKU), an autosomal recessive disease caused by
phenylalanine hydroxylase deficiency, results in high blood phe-
nylalanine (Phe) levels leading to neuropsychiatric and
neurocognitive symptoms. Pegvaliase is a PEGylated, bacterially
produced, phenylalanine ammonia lyase (PAL) enzyme substitu-
tion therapy that lowers blood Phe by converting Phe to trans-
cinnamic acid and ammonia. Protein therapeutics have been
shown to induce antidrug antibodies (ADA), which can impact
clinical safety and efficacy. Development of anti-polyethylene gly-
col (PEG) antibodies following treatment with PEGylated thera-
peutics has been reported, but the nature of these antibodies
and their clinical consequences are not well established.
Added value of this study
This is the first time that the immunogenicity of a chronically ad-
ministered, bacterially derived, PEGylated enzyme therapeutic
and its impact on safety and efficacy have been characterized.
During early treatment (≤6months after initiation), patients devel-
oped an immune response composed of anti-PEG antibodies and
anti-PAL immunoglobulin (Ig) M. During late treatment
(N6 months after initiation), anti-PEG antibodies reduced to base-
line levels and the immune response was mainly anti-PAL IgG
and IgM. Circulating immune complexes (CICs) and complement
activation were highest in early treatment and decreased as the
anti-PEG antibodies decreased, suggesting that the PEGylation
was effective in shielding binding of PAL-specific antibodies to
the drug and forming CICs. Hypersensitivity adverse events
were most frequent in early treatment and decreased as CICs
and complement activation lessened, but required slow titration
of the drug to efficacious levels. Blood Phe concentrations de-
creased over time as the immune response matured and
pegvaliase dosage increased.
Implications of all the available evidence
Patients treated with pegvaliase developed ADA responses that
matured to a clinical non responsive state over time, allowing sub-
stantial and sustained blood Phe reduction to be achieved with a
manageable safety profile for most patients.
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term AEs of arthralgia, arthritis, eye inﬂammation, eye irritation, eye
pain, joint stiffness, joint swelling, pyrexia, blurred vision and
polyarthritis, and the broad algorithmic anaphylactic reaction SMQ.
The anaphylactic reaction SMQ, hypersensitivity SMQ, and MedDRA
preferred terms were used to identify all AEs that could be component
manifestations of acute systemic hypersensitivity events and/or re-
ported as anaphylactic reactions. An allergist/immunologist indepen-
dent of the clinical site and sponsor reviewed all potential episodes of
acute systemic hypersensitivity events to identify the events consistent
with clinical criteria of anaphylaxis deﬁned by the National Institute of
Allergy and Infectious Diseases/Food Allergy and Anaphylaxis Network
[21] and Brown's severe criteria (ie, hypoxia, hypotension, or neurologic
compromise) [22].
2.3. Assays
Semi-quantitative direct-format electrochemiluminescent titer as-
says were used to measure PAL-speciﬁc IgM, PAL-speciﬁc IgG, PEG-
speciﬁc IgM, PEG-speciﬁc IgG, and anti-pegvaliase TAb titers in serum.
Pegvaliase NAb titers were measured using a semi-quantitative hybrid
ligand-binding liquid chromatography/tandem mass spectrometry
method. Pegvaliase-speciﬁc IgE was measured using an ImmunoCAP
assay thatwasmodiﬁed to include a stepwhereby IgG and IgMwere de-
pleted from serum before IgE assay. Complement-activating CICs con-
taining IgG and complement C3d were measured in serum using the
MicroVue CIC-Raji Cell Replacement (also referred to as CIC-C3d EIA)
assay(QuidelCorporation,SanDiego,CA).TheMicroVueassaywasmod-
iﬁed to measure CIC containing IgM and C3d. Decreases in C3 and C4
levelsweremonitored intheserumasbiomarkersof complementactiva-
tion. Phe concentrations weremeasured in deproteinized plasma using
ion exchange chromatography coupled with ninhydrin derivatization.
Details of each assaymethod are provided (see Supplemental Text).
2.4. Statistical analyses
The analysis population included all patients who ﬁrst initiated
pegvaliase in PRISM-1 and included all data collected in PRISM-1 and
PRISM-2 as of September 23, 2016. Baseline values were deﬁned as
the last available measurement prior to the ﬁrst administration of
pegvaliase in PRISM-1 (ie, pegvaliase-naïve baseline). Blood Phe data
were summarized at monthly intervals relative to baseline. The safety
analyses included data on the incidence, exposure-adjusted event rate,
and severity based on Common Terminology Criteria for Adverse Events
grade (grade 1, mild; grade 2, moderate; grade 3, severe but not imme-
diately life-threatening; grade 4, life- threatening; grade 5, death). An
exposure-adjusted event rate analysis was performed to control for dif-
ferences in duration of study participation.
Analysis of the association of CIC levels with blood Phe reduction
was performed by dividing patients into quartiles based on mean IgG-
CIC or IgM-CIC change from baseline over the entire treatment duration.
To evaluate the relationship between antibody titers and HAEs, patients
were divided into quartiles based on their mean antibody titer during
early (≤6months) or late (N6months) treatment phases plotted against
the number of HAEs. To evaluate associations between CIC concentra-
tions and exposure-adjusted AE rates, patients were divided into quar-
tiles based on theirmeanCIC change frombaseline level calculated from
all available results. Mean percent change in blood Phe was calculated
for each quartile at each evaluated time point. Patients with comple-
ment reduction b25% and ≥ 25% at Year 1 from baselinewere compared
to evaluate the association of complement reduction with AEs or labs of
interest.
3. Results
Two hundred and sixty-one patients enrolled in PRISM-1, as de-
scribed previously [4]. Mean ± standard deviation (SD) blood
concentration of Phe at baselinewas 1232.7±386.36 μmol/L, indicating
poor control.
3.1. Development of a biphasic immune response against pegvaliase
All patients developed TAb responses against pegvaliase (Supple-
mental Table 2), comprising subpopulations of treatment-induced
ADA to PAL and treatment-induced or treatment-boosted ADA to PEG.
The antibody response occurred in a biphasic manner; the response in
early treatment (≤6 months after treatment initiation) was primarily
composed of anti-PEG IgM, anti-PEG IgG, and anti-PAL IgM, whereas
the response in late treatment (N6 months) was composed of anti-PAL
IgM and anti-PAL IgG (Fig. 1a and b).
Anti-PEG antibody titers peaked at 1 to 3months after treatment ini-
tiation and then returned to baseline in most patients by 6 to 9months.
The incidence of anti-PEG IgG and anti-PEG IgM at baseline was 52.3%
and 45.0% (Supplemental Table 2), respectively, resulting from previous
exposures to PEG, which is within the range reported in the literature
[23–25]. The presence of anti-PEG antibodies at baselinewas not associ-
ated with an increased number of hypersensitivity events (Supplemen-
tal Table 3).
Anti-PAL IgM and IgG titers peaked at 3 and 6 months, respectively,
and remained stable through long-term treatment. The majority of pa-
tients developed a low-titer neutralizing ADA (NAb) response, which
remained stable through long-term treatment (mean NAb titer at
6 months: 415 [n = 192]; 1 year: 608 [n = 144]; 2 years: 661 [n =
91]; Supplemental Table 2).
Mean CIC levels were highest during early treatment and then de-
creased, corresponding with the change in anti-PEG responses over
time. Peak IgG-containing CIC levels were associated with declining C3
and C4 levels, indicating complement activation (Fig. 1c). Overall,
there was a high degree of consistency in the pattern of IgG CIC and
IgM CIC development over time, suggesting that CICs comprised both
IgM and IgG and can be detected with either assay method.
Antibody titers and IgG CIC levels either decreased (ie, anti-PEG an-
tibodies) or stabilized (ie, anti-PAL antibodies) over time and did not in-
crease after dose increases (Fig. 1c, Supplemental Fig. 1).
3.2. Immunogenicity and efﬁcacy
The immune response to pegvaliase was associated with blood Phe
reduction. During early treatment, anti-PEG IgG, anti-PEG IgM, anti-
PAL IgM, and CIC levels were highest, C3/C4 levels were lowest, and
plasma Phe concentrations were high (blood Phe [mean ± SD] =
922·5 ± 525·1 μmol/L, n= 237 at 3 months). In late treatment, anti-
PEG IgG, anti-PEG IgM, CIC, and C3/C4 levels returned toward baseline
values, pegvaliase dose was adjusted to individual blood Phe response,
and blood Phe concentrations decreased (blood Phe [mean ± SD] =
1232·7 ± 386·4 μmol/L at baseline; 564·5 ± 531·2 μmol/L at
12 months; 311·4 ± 426·6 μmol/L at 24 months).
As shown in Fig. 2, themagnitude of the NAb immune response was
inversely associated with the degree of blood Phe reduction. In early
treatment, patients in the lowest antibody titer quartile (Q1) experi-
enced the largest reductions in blood Phe. Following stabilization of an-
tibody titers and dose adjustment, mean blood Phe concentrations
continued to decrease, including in patients within higher antibody
titer quartiles (Q2, Q3, and Q4). A similar trend was observed across
all antibody types (non-neutralizing, neutralizing), analytes (anti-PAL,
anti-PEG, TAb), and isotypes (IgM, IgG). A related pattern was also ob-
served between the magnitude of the CIC levels and blood Phe reduc-
tion. Quartile analysis of IgG CIC levels (Fig. 3) indicated that patients
with less change from baseline in IgG CIC had more rapid mean blood
Phe reduction, although substantial blood Phe reduction was observed
in all IgG CIC quartiles.
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Fig. 1. Anti-pegvaliase ADA, CIC, and C3/C4 response (a) PAL IgG and PAL IgM titers, (b) PEG IgG and PEG IgM titers, (c) percent change in CIC and C3/C4 levels from baseline,
(d) hypersensitivity adverse events. ADA, antidrug antibody; C3/C4 complement components 3 and 4; CIC, circulating immune complex; IgG, immunoglobulin G; IgM,
immunoglobulin M; PAL, phenylalanine ammonia lyase; PEG, polyethylene glycol.
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3.3. Immunogenicity and safety
Almost all patients (93.5%) experienced HAEs. HAEs occurred most
frequently in early treatment (15.6 events/patient-year) when anti-
PEG IgM, anti-PEG IgG, and anti-PAL IgM responses were peaking, CIC
levels were high, and C3/C4 levels were low (Fig. 1d). The frequency
of HAEs declined over time (HAE rate after 6 months = 4.0 events/
patient-year), as the anti-PAL antibody response stabilized and the
anti-PEG response, CIC, and complement activation decreased over
time.
A total of 17 events in 12 patients (4.6%) were adjudicated by an
independent allergist as acute systemic hypersensitivity events, with
15 of these events occurring in the ﬁrst year of treatment. No patient
required intubation or vasopressor treatment to treat acute hypersensi-
tivity, and all the events resolved without sequelae. Pegvaliase-speciﬁc
IgE was not detected in serum from patients at or near the time of the
event. Six patients discontinued from the study after these events
while 6 continued dosing; of those, 2 had additional events that did
not occur directly after restarting pegvaliase [26].
Antibody titers were not associatedwith HAEs during any treatment
phase, as demonstrated in Supplemental Fig. 2 using TAb titers as an
example. There was signiﬁcant overlap of HAEs in patients from all
TAb quartiles; thus, antibody titers were not predictive of development
of HAEs.
Fig. 2. NAb quartiles and blood Phe. Subject data were divided into quartiles based on mean post-baseline antibody titer (a) ≤6 months after start of treatment, (b) N6 months to ≤1 year
after start of treatment, and (c) N1 year after start of treatment. Observed blood Phe was deﬁned as the last available post-baseline blood Phe within each time interval. NAb, neutralizing
antibody; Phe, phenylalanine; Q, quartile.
Fig. 3. IgG CIC quartiles and blood Phe. Subject data were divided into quartiles based onmean CIC change from baseline level calculated from all available results, whichwas plottedwith
mean blood Phe concentration for each quartile at each evaluated time point. The averages of all valueswithin each interval are plotted. Due to differences in the duration of time on study
for individual patients and discontinuation rates, there are a limited number of patients with data at time points after week 84. CIC, circulating immune complex; IgG, immunoglobulin G;
Phe, phenylalanine; Q, quartile.
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As shown in Table 1, AEs, serious AEs (SAEs), HAEs, acute systemic
hypersensitivity events, arthralgia/arthritis, and lymphadenopathy last-
ing ≥14 days were highest in patients with the largest IgG CIC increase
frombaseline. Results for IgMCICwere similar to IgG CIC (Supplemental
Table 4). The trend observed with SAEs was driven by acute systemic
hypersensitivity events.
Overall, exposure-adjusted AE rates were similar for patients with
b25% or N 25% C3 reduction from baseline at 1 year with the exception
of acute systemic hypersensitivity events, which occurred at a higher
rate in patients with ≥25% C3 reduction (Table 2). Results were similar
for C3 and C4.
No speciﬁc antibody titer value, CIC level, or complement level was
predictive of AEs, including acute systemic hypersensitivity events.
Wide individual variability was observed in antibody titers, CIC levels,
and complement levels between patients with and without acute sys-
temic hypersensitivity events (Fig. 4).
No clinical observations or laboratory abnormalities suggestive of
pegvaliase-associated IC-mediated end-organ damage, including renal
failure, central nervous systemmanifestations (such as cerebrovascular
accidents or transient ischemic attacks), myocardial ischemic events, or
hemolytic anemia events were observed in any pegvaliase-treated
patients.
4. Discussion
Historically, reports characterizing immunogenicity against bio-
logics have been limited to a description of ADA incidence. However,
many of the immune-mediated clinical effects attributed to ADAs re-
quire the formation of a drug/ADA IC intermediate, which is seldom
measured and can have a variety of downstream effects. In this study,
we report on the immunogenicity of pegvaliase using an extensive
monitoring strategy, includingmeasurement of antibody titers ofmulti-
ple isotypes and speciﬁcities, assessment of enzymatic neutralization,
measurement of IgM and IgG IC, and analyses of biomarkers of comple-
ment activation. These ﬁndings lead to a clear understanding of the im-
munogenicity of pegvaliase and its impact on efﬁcacy and safety of the
drug, enabling the design of a dosing paradigm aimed to achieve maxi-
mum efﬁcacy while minimizing AEs.
Patients treated daily with a subcutaneous injection of pegvaliase
developed antibodies against PAL and PEG. The sustained anti-PAL re-
sponse is consistent with a typical CD4-dependent antibody response
induced against a foreign protein [27]. The transient nature of the
anti-PEG responsemay result from a low-afﬁnity, CD4-independent an-
tibody response typically observed against non-protein repetitive anti-
gens [13]. CD4-independent antibody responses to PEG have been
reported for both nonclinical and clinical studies. In nearly all animal
studies, anti-PEG antibody responses were largely IgM and were tran-
sient [28,29].
Two of 13 approved PEGylated biotherapeutics, pegaspargase and
pegloticase, induce anti-PEG antibodies associated with loss of efﬁcacy
and increased risks for hypersensitivity reactions [16]. With both, the
anti-PEG antibody responseswere sustained and transitioned from a re-
sponse predominantly IgM to an IgG isotype. This is in contrast to the
transient and predominantly IgM and low-titer IgG responses to PEG
Table 1
Adverse events by IgG circulating immune complex change from baseline quartiles (intent-to-treat population, N= 261).
Quartile 1
(n= 65)
Quartile 2
(n = 65)
Quartile 3
(n= 65)
Quartile 4
(n= 64)
Total
(n= 259)
IgG CIC change from baseline quartile range (min–max) (−22.76–10.85) (10.98–21.11) (21.54–35.20) (35.46–242.25)
Total treatment exposure, person-yearsa 125.5 125.3 84.6 65.8 401.2
Event rate, per person-year (total number of events)
Adverse events 22.58 (2833) 28.74 (3603) 34.37 (2909) 45.10 (2967) 30.69 (12312)
Serious adverse events 0.05 (6) 0.18 (22) 0.11 (9) 0.35 (23) 0.15 (60)
Hypersensitivity adverse events 5.83 (731) 7.67 (961) 7.46 (631) 9.41 (619) 7.33 (2942)
Acute systemic hypersensitivity events of anaphylaxis 0 0.02 (2) 0.04 (3) 0.18 (12) 0.04 (17)
Arthralgia/arthritis 2.45 (308) 2.39 (300) 2.71 (229) 4.09 (269) 2.76 (1106)
Generalized skin reaction ≥14 days duration 0.52 (65) 0.42 (53) 0.39 (33) 0.30 (20) 0.43 (171)
Urticaria ≥14 days duration 0.02 (3) 0.02 (3) 0.02 (2) 0.03 (2) 0.02 (10)
Lymphadenopathy ≥14 days duration 0.09 (11) 0.12 (15) 0.11 (9) 0.29 (19) 0.13 (54)
Serum sickness-like reaction 0.02 (2) 0.02 (2) 0.02 (2) 0.02 (1) 0.02 (7)
Infection and infestations ≥30 days duration 0.16 (20) 0.23 (29) 0.25 (21) 0.23 (15) 0.21 (85)
Infection serious adverse events 0.01 (1) 0.03 (4) 0 0.02 (1) 6 (0.01)
Ischemic heart disease 0 0 0 0 0
Event rate was calculated as total number of events divided by person-years of exposure.
a Total treatment exposure was the aggregated duration of treatment across all patients (for each patient, time from the ﬁrst dose to the last dose administered across all studies in
which the patient was enrolled). Intervals of missing doses that were N 28 consecutive days were excluded from the calculation of treatment duration. CIC, circulating immune complex;
IgG, immunoglobulin G.
Table 2
Adverse events by C3 reduction from baseline at year 1 (intent-to-treat population, N= 233).
Percent reduction in C3 from baseline at year 1 b25%
(n= 67)
≥25%
(n= 98)
≥25% and b 50%
(n= 59)
≥50%
(n= 39)
Total treatment exposure, person-yearsa 120.2 188.4 115.7 72.7
Event rate, per person-year (total number of events)
Any adverse event 31.3 (3760) 29.5 (5562) 26.0 (3005) 35.2 (2557)
Any serious adverse event 0.1 (12) 0.1 (26) 0.1 (16) 0.1 (10)
Any hypersensitivity adverse event 7.1 (857) 7.2 (1363) 7.2 (834) 7.3 (529)
Acute systemic hypersensitivity event of anaphylaxis 0.01 (1) 0.06 (12) 0.05 (6) 0.08 (6)
Arthralgia/arthritis 2.9 (351) 2.6 (490) 2.3 (262) 3.1 (228)
Generalized skin reaction ≥14 days duration 0.6 (68) 0.4 (67) 0.4 (48) 0.3 (19)
Persistent urticaria ≥ 14 days duration 0.02 (2) 0.03 (5) 0.03 (3) 0.03 (2)
Event rate was calculated as total number of events divided by person-years of exposure.
a Total treatment exposure was the aggregated duration of treatment across all patients (for each patient, time from the ﬁrst dose to the last dose administered across all
studies in which the patient was enrolled). Intervals of missing doses that were N 28 consecutive days were excluded from the calculation of treatment duration. C3, comple-
ment component 3.
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observed with pegvaliase, perhaps attributable to the induction, titra-
tion, and daily maintenance dosing regimen leading to desensitization
over time. Anti-PEG antibodies in healthy individuals have been re-
ported due to exposure to PEG-containing compounds in cosmetics,
pharmaceuticals, and processed food products, but the presence of
these antibodies has not been associated with any pathology. A subset
of patients in the PRISM trials enrolled with pre-existing anti-PEG IgG
and/or anti-PEG IgM, consistent with the baseline positivity rates re-
ported in the literature [24,25,27]. Presence of anti-PEG antibodies at
baseline did not impact pegvaliase safety.
The data presented herein suggest the change in immune response
over time inﬂuences the dosing necessary to achieve efﬁcacy. High
levels of IgM observed during early treatment (≤6 months after treat-
ment initiation) are an efﬁcient activator of the classical complement
pathway. In contrast, the immune response in late treatment
(N6 months after treatment initiation) is composed predominately of
anti-PAL IgG antibodies, which are less likely to bind to the drug product
and ﬁx complement due to the masking of PAL epitopes by extensive
PEGylation on the surface of the drug. Fig. 5 illustrates our model that
CIC levels are highest in early treatment despite sustained anti-PAL
ADA levels.
The time course of ADA maturation, IC formation, and complement
activation drove the need for an induction/titration dosing schedule
necessary to achieve efﬁcacious doses in later treatmentwhileminimiz-
ing the occurrence of HAEs during early treatment. The suggested dos-
ing schedule includes a low starting dose of 2.5 mg/week for 4 weeks,
followed by a gradual titration over ≥5 weeks up to 20 mg/day and a
delayed escalation from 20 to 40 mg/day. The maintenance dose of 20
or 40 mg/day is individualized based on patient tolerability and blood
Phe concentrations. For further details on the dosing schedule, please
refer to the Palynziq prescribing information [10]. The overlap in the
range of antibody titers between the different dose groupsmakes it dif-
ﬁcult to associate a speciﬁc antibody titer with a speciﬁc dose required
to achieve Phe reduction. For this reason,monitoring of blood Phe is rec-
ommended for managing patients to ensure the lowest dose is used to
achieve reduction in blood Phe.
Data from this study demonstrated that there was an inverse associ-
ation between the magnitude of the ADA response and the degree of
blood Phe reduction. Nevertheless, patients with the highest ADA titers
could still achieve a meaningful Phe response once the immune re-
sponse matured and their dose increased with long-term treatment.
The mechanisms by which ADAmay impact pegvaliase efﬁcacy include
immune-mediated plasma clearance of the drug via the reticuloendo-
thelial system and reduction of enzyme activity following NAb binding.
In this study, patients with a wide range of NAb responses were able to
attain sustained reductions in blood Phe, suggesting that the neutraliz-
ing response to pegvaliase was a minor component of the overall im-
mune response and only partially inhibited in vivo enzymatic activity
(Fig. 2). Overall, no speciﬁc threshold of antibody titer, isotype, or spec-
iﬁcity, including NAb, was predictive of the degree of reduction or dose
needed to achieve substantial reduction in blood Phe.
In this study, no speciﬁc CIC level was predictive of the occurrence of
an acute systemic hypersensitivity event despite an association be-
tween the magnitude of CIC change from baseline and frequency of
Fig. 4. Peak IgG-C3d CIC concentrations in patientswith andwithout acute systemic hypersensitivity events. Therewas considerable overlap in IgG CIC levels for patients with andwithout
acute systemic hypersensitivity events, and patients with the highest IgG CIC levels did not experience acute systemic hypersensitivity events. C3d, complement component 3d; CIC,
circulating immune complex; IgG, immunoglobulin G.
Fig. 5. Illustration of the changing CIC landscape in early vs. late treatment. Early in treatment (0–6months), CICs contain anti-PEG IgG, anti-PEG IgM, anti-PAL IgG and anti-PAL IgM. Later
in treatment (N6 months), there are fewer CICs formed by anti-PAL IgG and anti-PAL IgM only. CIC, circulating immune complex; IgG, immunoglobulin G; IgM, immunoglobulin M; PAL,
phenylalanine ammonia lyase; PEG, polyethylene glycol.
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acute systemic hypersensitivity events. Reasons for this may be multi-
factorial, including the methods used to detect CICs, which detected
all CICs rather than those that are antigen-speciﬁc, contribution of
other mechanisms such as IgG-mediated hypersensitivity reactions via
binding to Fc gamma receptors, and presence of other unidentiﬁed co-
factors that might increase the risk of hypersensitivity in some patients.
Although pegvaliase has potential for IC-mediated toxicity, a review of
the safety data thus far has shown no evidence of pegvaliase-
associated end-organ damage due to IC deposition with 401 patient-
years of exposure, including 20 patients with N3 years of exposure.
In summary, these results support the efﬁcacy of pegvaliase for the
treatment of adults with PKU, with a manageable safety proﬁle for
most participants. Pegvaliase has been shown to have improved safety
and efﬁcacy when introduced slowly with incremental dose increases
to allow the immune system to stabilize. The risk of AEs is highest in
early treatment during induction/titration dosing, when the immune
response is immature and patients are receiving low, sub-therapeutic
doses. In late treatment, the immune response matures and stabilizes,
and the occurrence of HAEs decreases due to a reduction in IC formation
and complement activation, despite dose increases that allow the ma-
jority of patients to achieve substantial and durable blood Phe efﬁcacy.
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